Trends in CDMO of High Potency Drugs

Trends in CDMO of High Potency Drugs

The major revenue-generating part of the pharmaceutical industry is the high potency drug market. The high potency drug market holds significant potential. There is great demand for oncology and other high potency drugs such as IV fluids and ADCs.

With respect to demand, buyers are in need of high-capacity manufacturers who have lyophilization ability in injectable dosage forms, one who can reach their API OEL limits, and one who has experience in handling high potency drugs. But with regards to the side of supply, there aren’t sufficient CMOs who can meet the buyers’ needs as demanded.

This article focuses on the regional distribution of suppliers and how the increasing demand for high potency active pharmaceutical ingredient drugs is affecting the CMO market regarding investing/upgrading in new capital, new facilities, capacity expansion, acquisitions, mergers, etc. Continue reading to learn more.

Potential for Strong Growth

Companies that deal in innovations focus on the use of high potency active pharmaceutical ingredients to provide new patient therapies. They are doing this by providing well-tolerated, low-dose, and effective medicine. Various oncology molecules in the pipeline of huge pharmaceutical companies are significantly potent, the major push for high potency active pharmaceutical ingredient drugs CMO market.

Regardless of the high cost of production and rigorous regulatory requirements, CMOs are concentrating on the manufacturing of high-potency drugs to take over this market gap. As the demand for high potency lyophilized formulations increases, there is a need for a lot more capable CMPs to meet the ever-increasing demand.

Is there Sufficient Supply in the Market?

There is a fast rate of growth in the high potency market. In today’s market, the capacity of the CMOs is lesser than the demand for injectable high potent drugs. This demand is majorly for lyophilized products. A major constraint of the market is the need for specified suppression services to take care of high potency drugs.

Nonetheless, recognizing an increase in the need for anti-cancer drugs, various companies are concentrating on new capital. They do this to increase capacity.

Trends

As the CMO market of high potency drugs continues to expand, suppliers have found the market to be attractive to invest in the new inhibition facilities. Manufacturers who offer commercial-scale high potency drug production have improved their capacity to meet the demand.

Lately, CMOs of high potency drugs have capitalized on high potency drug production capabilities. So also, producers of high potency active pharmaceutical ingredients have increased their capacity to meet the ever-increasing demand.  

Today, there is no overcapacity in the market, yet suppliers need capitalization to meet the envisioned growing demand of huge pharmaceutical companies.

The high potency active pharmaceutical ingredient drug market is expected to experience strong growth because of patent expirations. There is also an increasing trend of pharmaceutical companies to engage with a single partner who has the capabilities to provide high potency active pharmaceutical ingredients development and production services. This will help to reduce the cost and time of drug development.

AbbVie is the best potent drug contract manufacturing company. We handle your product as our own. The nature of your biological drug notwithstanding, you can count on us when it comes to aseptic fill-finish manufacturing. We will provide reliable and safe products that patients are ready to use.